atherosclerosi
increasingli
view
inflammatori
process
number
infecti
agent
implic
pathogenesi
coronari
arteri
diseas
chlamydia
pneumonia
popular
wellstudi
pathogen
difficult
prove
causal
relationship
requir
fulfil
koch
postul
first
develop
late
establish
infecti
agent
caus
diseas
process
paper
review
evid
chlamydia
pneumonia
infect
contribut
factor
atherosclerosi
diseas
examin
seroepidemiolog
histopatholog
studi
well
anim
model
use
koch
postul
provid
analysi
current
clinic
trial
data
n
publish
elsevi
inc
nfectiou
agent
propos
potenti
caus
atherosclerosi
sinc
late
earli
tabl
paper
publish
frothingham
state
bacut
infecti
diseas
may
caus
pretti
gener
lesion
throughout
arteri
system
either
diffus
action
toxin
widespread
invas
arteri
system
infect
organ
exact
natur
lesion
human
case
final
result
well
work
outq
nearli
year
later
still
grappl
question
certainli
first
instanc
infect
link
chronic
diseas
welldocu
associ
revolution
diseas
manag
includ
helicobact
pylori
peptic
ulcer
diseas
human
papillomaviru
cervic
cancer
human
herpesviru
kaposi
sarcoma
hepat
b
hepatocellular
carcinoma
although
diseas
scarlet
fever
diphtheria
measl
cite
plausibl
contributor
atherosclerot
process
earli
centuri
control
pathogen
ensu
year
given
rise
new
cast
suspect
agent
infecti
agent
implic
atherosclerosi
past
year
includ
cytomegaloviru
cmv
herp
simplex
viru
hsv
h
pylori
chlamydia
pneumonia
like
pathogen
formerli
question
exposur
organ
occur
rel
earli
life
set
stage
potenti
role
initi
pathogenesi
atherosclerot
process
furthermor
organ
similar
oblig
intracellular
pathogen
capabl
maintain
chronic
persist
state
host
data
link
herp
virus
atherosclerosi
first
came
marek
avian
herp
viru
infect
diseasefre
chicken
viru
produc
arteri
lesion
member
herpesvirida
famili
cmv
associ
increas
risk
atherosclerosi
death
coronari
diseas
cardiac
transplant
prior
cmv
infect
also
link
increas
risk
restenosi
percutan
coronari
intervent
howev
data
conflict
sever
prospect
nest
casecontrol
studi
show
dispar
result
wherea
atherosclerosi
risk
commun
studi
found
high
level
cmv
antibodi
correl
increas
risk
coranari
arteri
diseas
cad
followup
physician
health
studi
find
associ
cmv
hsv
antibodi
myocardi
infarct
mi
stroke
followup
period
cardiovascular
health
studi
found
antibodi
hsv
cmv
associ
increas
risk
mi
cardiovascular
death
elderli
patient
number
seroepidemiolog
studi
suggest
associ
h
pylori
coronari
diseas
mani
studi
adjust
appropri
potenti
confound
socioeconom
statu
howev
casecontrol
studi
adjust
age
sex
cardiac
risk
factor
social
class
found
correl
h
pylori
coronari
diseas
relationship
may
caus
increas
preval
virul
h
pylori
strain
patient
unlik
organ
question
h
pylori
detect
atherosclerot
plaqu
addit
sever
studi
shown
infecti
burden
exampl
number
pathogen
individu
expos
determin
serolog
associ
extent
atherosclerot
diseas
risk
cardiovascular
death
presenc
chronic
respiratori
tract
urinari
tract
dental
infect
associ
studi
increas
risk
carotid
atherosclerosi
conflict
data
literatur
regard
associ
infecti
pathogen
coronari
event
make
difficult
draw
definit
conclus
regard
role
diseas
pathogenesi
therefor
potenti
therapeut
intervent
c
pneumonia
best
describ
pathogen
paper
thu
review
current
data
c
pneumonia
potenti
role
pathogenesi
atherosclerot
diseas
c
pneumonia
oblig
intracellular
bacterium
capabl
chronic
persist
infect
first
identifi
year
ago
caus
acut
upper
lower
respiratori
tract
infect
uniqu
development
cycl
involv
morpholog
form
elementari
bodi
reticul
bodi
former
infecti
form
adapt
extracellular
surviv
wherea
latter
metabol
activ
divid
form
adapt
intracellular
multipl
addit
organ
may
evolv
bpersist
bodi
q
intracellular
metabol
inact
nonrepl
viabl
form
allow
maintain
chronic
infect
therebi
state
chronic
inflamm
may
contribut
atherosclerot
process
c
pneumonia
infect
ubiquit
antibodi
preval
age
age
account
communityacquir
pneumonia
pharyng
bronchiti
sinus
robert
koch
develop
follow
criteria
must
satisfi
prove
specif
organ
caus
specif
diseas
pathogen
must
present
nearli
case
diseas
pathogen
must
isol
diseas
host
grown
cultur
diseas
must
reproduc
cultur
inocul
healthi
host
organ
must
recov
experiment
infect
host
koch
use
criteria
establish
bacillu
anthraci
mycobacterium
tuberculosi
vibrio
cholera
etiolog
anthrax
tuberculosi
cholera
respect
sinc
postul
use
determin
causal
relationship
organ
clinic
diseas
syndrom
includ
hiv
aid
well
sever
acut
respiratori
syndrom
sar
associ
coronaviru
sar
howev
sever
limit
koch
postul
first
bacteria
part
normal
flora
usual
caus
diseas
becom
pathogen
certain
situat
immunocompromis
host
penetr
deep
tissu
second
infect
organ
develop
overt
clinic
diseas
host
immun
system
may
clear
organ
host
may
develop
subclin
infect
third
organ
difficult
cultur
cultur
vitro
eg
mycobacterium
lepra
may
lack
anim
model
infect
final
someth
describ
koch
postul
may
use
prove
causal
erad
pathogen
result
cure
imped
diseas
progress
keep
consider
mind
use
koch
postul
framework
assess
potenti
role
c
pneumonia
atherogenesi
discuss
line
evid
support
koch
first
postul
includ
seroepidemiolog
studi
histopatholog
detect
organ
atherosclerot
lesion
first
report
possibl
associ
c
pneumonia
atherosclerosi
describ
casecontrol
studi
finnish
men
admit
acut
mi
ami
match
control
ami
patient
elev
chlamydi
immunoglobulin
ig
g
iga
titer
compar
control
separ
nest
casecontrol
studi
patient
helsinki
heart
studi
group
note
time
increas
risk
cardiac
event
among
patient
chronic
chlamydi
infect
adjust
classic
coronari
risk
factor
studi
publish
author
show
concurr
elev
crp
patient
chlamydi
seroposit
increas
coronari
risk
danesh
et
al
review
seroepidemiolog
studi
includ
describ
literatur
includ
case
control
c
pneumonia
antibodi
posit
associ
coronari
diseas
studi
cerebrovascular
diseas
studi
major
studi
odd
ratio
exceed
studi
adjust
potenti
confound
studi
fairli
heterogen
vari
popul
studi
criteria
use
defin
cardiovascular
diseas
degre
adjust
confound
variabl
howev
overal
consist
find
suggest
possibl
associ
c
pneumonia
coronari
diseas
howev
posit
find
critic
lack
standard
serolog
method
across
studi
major
studi
use
microimmunofluoresc
mif
serolog
test
sinc
first
develop
assay
recogn
problemat
test
standard
subject
interlaboratori
variat
interpret
slide
requir
experienc
microscopist
larg
subject
compon
assay
lead
poor
reproduc
difficult
establish
rule
diagnosi
c
pneumonia
infect
singl
mif
titer
especi
children
acut
culturedocu
infect
occur
without
posit
mif
high
preval
infect
among
adult
popul
also
complic
interpret
mif
result
one
studi
healthi
adult
found
cultur
polymeras
chain
reaction
pcr
neg
individu
evid
bacuteq
infect
mif
addit
problem
inher
assay
abovement
studi
inconsist
serolog
criteria
use
defin
past
chronic
persist
infect
mif
assay
igg
iga
antibodi
titer
cutoff
vari
studi
case
titer
select
post
hoc
data
analysi
determin
cutoff
provid
strongest
associ
case
investig
use
differ
criteria
differ
studi
anoth
sourc
potenti
bia
lack
blind
microscopist
perform
mif
assay
diseas
statu
patient
studi
indic
blind
occur
furthermor
major
earlier
studi
crosssect
casecontrol
retrospect
recent
prospect
studi
confirm
associ
seroposit
c
pneumonia
atherosclerosi
danesh
et
al
publish
larg
casecontrol
studi
nest
prospect
cohort
british
men
follow
period
includ
men
fatal
nonfat
mi
ageand
frequencymatch
control
case
compar
control
posit
c
pneumonia
titer
yield
odd
ratio
coronari
heart
diseas
adjust
smoke
socioeconom
statu
group
perform
updat
metaanalysi
includ
studi
prospect
studi
publish
may
studi
includ
total
case
nonfat
mi
coronari
death
adjust
classic
coronari
risk
factor
combin
odd
ratio
coronari
diseas
prospect
studi
confid
interv
compar
observ
earlier
metaanalysi
publish
group
recent
metaanalysi
seroepidemiolog
studi
januari
decemb
also
found
odd
ratio
crosssect
casecontrol
studi
higher
prospect
studi
vs
overal
odd
ratio
although
entir
rule
possibl
associ
c
pneumonia
atherosclerosi
recent
data
suggest
strong
causal
relationship
less
like
presenc
c
pneumonia
atherosclerot
plaqu
first
describ
shor
et
al
organ
identifi
electron
microscopi
em
chlamydia
immunoperoxidas
stain
genusspecif
speciesspecif
monoclon
antibodi
postmortem
atheroma
respect
none
control
case
gibb
et
al
review
studi
detect
c
pneumonia
atherosclerot
specimen
use
varieti
detect
techniqu
includ
pcr
immunocytochem
stain
immunofluoresc
situ
hybrid
ish
direct
cultur
organ
identifi
specimen
atherosclerosi
versu
specimen
without
atherosclerosi
boman
hammerschlag
perform
even
extens
review
studi
publish
includ
total
atherosclerot
specimen
preval
c
pneumonia
atheroma
vari
significantli
depend
particular
detect
method
use
immunocytochemistri
pcr
commonli
use
techniqu
includ
direct
cell
cultur
em
ish
total
specimen
posit
immunostain
use
chlamydia
genusspecif
antibodi
specimen
posit
immunostain
use
c
pneumoniaespecif
antibodi
em
gave
posit
result
specimen
percentag
posit
pcr
significantli
less
specimen
wherea
direct
cultur
yield
preval
specimen
ish
posit
specimen
examin
direct
cultur
organ
gold
standard
howev
c
pneumonia
difficult
grow
cell
cultur
make
insensit
test
reflect
limit
koch
postul
lack
proper
bgold
standardq
make
interpret
result
difficult
although
preval
organ
atheroma
may
high
howev
specimen
test
posit
independ
techniqu
consid
true
posit
preval
reduc
significantli
specimen
analyz
c
pneumonia
techniqu
test
posit
least
assay
although
recoveri
c
pneumonia
direct
cultur
difficult
number
group
isol
organ
atherosclerot
plaqu
c
pneumonia
first
isol
direct
cultur
atheroma
patient
sever
coronari
diseas
maa
et
al
isol
viabl
c
pneumonia
atheroma
patient
undergo
coronari
bypass
surgeri
half
isol
capabl
perman
propag
serial
subcultur
organ
found
nonatherosclerot
control
sampl
howev
group
fail
identifi
c
pneumonia
patient
undergo
atherectomi
koch
postul
diseas
must
reproduc
cultur
inocul
healthi
host
studi
carri
koch
third
postul
exactli
describ
exampl
isol
organ
diseas
host
grown
cultur
subsequ
inocul
cultur
isol
healthi
host
caus
atherosclerot
diseas
howev
number
anim
studi
shown
inocul
c
pneumonia
healthi
host
lead
atherosclerot
diseas
compar
uninfect
control
anim
fong
et
al
laitinen
et
al
demonstr
intranas
inocul
c
pneumonia
new
zealand
white
nzw
rabbit
fed
normal
diet
led
format
atherosclerot
plaqu
compar
uninfect
control
nzw
rabbit
chang
observ
week
one
studi
week
anim
note
lesion
contain
foami
macrophag
spindl
cell
prolifer
smooth
muscl
cell
moaz
et
al
found
intranas
inocul
c
pneumonia
apolipoprotein
edefici
mice
hyperlipidem
mous
model
fed
normal
diet
acceler
progress
atherosclerot
lesion
compar
uninfect
control
mice
lesion
area
inner
curvatur
aortic
arch
time
greater
week
week
respect
infect
compar
control
mice
muhlstein
et
al
random
nzw
rabbit
fed
cholesterolenhanc
diet
receiv
intranas
inocul
c
pneumonia
salin
group
random
cours
azithromycin
therapi
maxim
intim
thicken
plaqu
area
index
significantli
greater
infect
untreat
rabbit
compar
uninfect
control
maxim
intim
thicken
plaqu
area
index
infect
treat
rabbit
uninfect
control
differ
anim
studi
describ
c
pneumonia
could
demonstr
vessel
wall
immunohistochem
stain
direct
cultur
intranas
inocul
sever
way
c
pneumonia
may
contribut
pathogenesi
atherosclerot
diseas
first
c
pneumonia
may
caus
initi
injuri
induc
atherosclerot
process
second
organ
may
acceler
progress
preexist
diseas
third
may
contribut
diseas
complic
plaqu
ruptur
mi
final
may
innoc
bystand
persist
vascular
cell
contribut
patholog
abnorm
propos
model
pathogenesi
describ
follow
first
organ
gain
access
vascular
endothelium
local
infect
respiratori
tract
infect
leukocyt
may
dissemin
organ
throughout
bodi
activ
macrophag
carri
organ
infiltr
subendotheli
layer
coronari
arteri
organ
act
stimulu
chronic
inflamm
induc
product
tissu
factor
leukocyt
adhes
molecul
inflammatori
cytokin
includ
tumor
necrosi
factor
tnf
interleukin
tnfa
observ
increas
express
leukocyt
adhes
molecul
inhibit
lipoprotein
lipas
lead
alter
lipid
metabol
accumul
triglycerid
bloodstream
increas
express
adhes
molecul
promot
leukocyt
adher
migrat
intim
inflamm
inflammatori
cytokin
togeth
act
stimul
fibroblast
smooth
muscl
cell
prolifer
also
promot
hypercoagul
state
activ
platelet
increas
hepat
synthesi
acutephas
protein
induc
tissu
factor
releas
endothelium
activ
coagul
cascad
bacteri
lipopolysaccharid
antigen
act
potent
stimulu
macrophag
activ
addit
bind
lowdens
lipoprotein
could
modifi
lipoprotein
make
toxic
immunogen
endotheli
cell
subsequ
lead
foam
cell
format
persist
growth
organ
situ
lead
state
chronic
inflamm
platelet
activ
vasospasm
thrombosi
c
pneumonia
may
contribut
atherosclerosi
via
antigen
mimicri
autoimmun
chlamydi
heat
shock
protein
isol
macrophag
within
atheromat
tissu
coloc
homolog
human
hsp
potenti
mechan
atherogenesi
suggest
persist
infect
c
pneumonia
express
may
trigger
autoimmun
reaction
human
hsp
also
observ
activ
macrophag
stimul
tnfa
matrix
metalloproteinas
express
may
contribut
plaqu
weaken
subsequ
ruptur
although
describ
koch
origin
postul
line
evid
may
use
determin
role
c
pneumonia
pathogenesi
coronari
diseas
includ
data
secondari
prevent
trial
human
be
c
pneumonia
involv
atherogenesi
presum
view
composit
cv
event
reflect
combin
least
follow
clinic
end
point
fatalnonfat
mi
unstabl
angina
unplan
revascular
stroke
allcaus
mortal
studi
includ
cardiovascular
death
end
point
tthe
decreas
cv
event
statist
signific
month
although
differ
persist
month
modifi
risk
factor
treatabl
antibiot
therapi
way
hyperlipidemia
manag
lipidlow
agent
complet
clinic
trial
summar
tabl
ongo
trial
tabl
gupta
et
al
publish
first
random
doubleblind
placebocontrol
secondari
prevent
trial
stabl
postmi
male
patient
known
seroposit
c
pneumonia
subject
random
receiv
cours
azithromycin
placebo
month
followup
event
rate
treatment
group
compar
placebo
group
statist
signific
reduct
albeit
small
number
roxithromycin
nonqwav
coronari
syndrom
roxi
studi
secondari
prevent
trial
patient
unstabl
angina
nonqwav
myocardi
infarct
nqwmi
random
receiv
cours
roxithromycin
placebo
note
c
pneumonia
seroposit
use
entri
criterion
statist
signific
reduct
recurr
cardiovascular
event
treatment
group
compar
placebo
arm
tripl
end
point
recurr
angina
ami
death
month
followup
differ
persist
longer
statist
signific
azithromycin
coronari
arteri
diseas
elimin
myocardi
infect
chlamydia
academ
trial
secondari
prevent
trial
coronari
patient
seroposit
c
pneumonia
random
receiv
cours
azithromycin
placebo
month
followup
statist
signific
reduct
creactiv
protein
compar
placebo
howev
differ
clinic
event
fatalnonfat
mi
unstabl
angina
unplan
coronari
revascular
stroke
antibodi
titer
observ
group
year
followup
continu
differ
clinic
end
point
clarithmyocin
acut
coronari
syndrom
patient
finland
clarifi
studi
demonstr
reduct
cardiovascular
event
patient
unstabl
angina
nqwmi
treatment
period
clarithromycin
initi
time
present
compar
placebo
median
period
day
treat
patient
rel
risk
ratio
cardiovascular
event
weekli
intervent
zithromax
atherosclerosi
relat
disord
wizard
trial
largest
clinic
trial
publish
date
includ
patient
prior
mi
posit
serolog
random
receiv
placebo
azithromycin
mg
time
day
first
day
follow
mg
week
week
although
nonsignific
earli
treatment
benefit
sustain
throughout
entir
followup
period
brassard
et
al
conduct
nest
casecontrol
studi
subject
statu
postmi
note
nonstatist
signific
reduct
risk
acut
mi
patient
receiv
prescript
antichlamydi
antibiot
preced
month
intraconari
stent
antibiot
regimen
studi
poststent
patient
found
although
overal
differ
rate
angiograph
restenosi
patient
receiv
roxithromycin
compar
placebo
patient
high
c
pneumonia
antibodi
titer
receiv
antibiot
significantli
lower
restenosi
rate
compar
result
clinic
trial
respect
potenti
role
antibiot
manag
coronari
arteri
diseas
inconclus
studi
vari
number
way
includ
patient
popul
select
c
pneumonia
seroposit
durat
followup
antibiot
use
dosag
durat
antibiot
treatment
patient
stabl
coronari
diseas
differ
present
acut
coronari
syndrom
patient
unstabl
plaqu
may
higher
infect
burden
like
activ
infect
thu
may
benefit
directli
antibiot
therapi
two
publish
trial
roxi
clarifi
involv
patient
unstabl
angina
nqwmi
demonstr
statist
signific
reduct
cardiovascular
event
treatment
academ
wizard
trial
conduct
patient
rel
stabl
coronari
diseas
yield
neg
result
one
potenti
explan
dispar
organ
may
remain
inact
nonrepl
form
stabl
atherosclerot
plaqu
make
less
suscept
effect
antibiot
c
pneumonia
play
role
coronari
arteri
diseas
although
tradit
criteria
koch
postul
entir
fulfil
evid
suggest
organ
may
simpli
innoc
bystand
seroepidemiolog
data
provid
modest
support
associ
atherosclerosi
c
pneumonia
although
recent
prospect
studi
convinc
interpret
find
well
find
clinic
trial
import
consid
limit
current
serolog
test
unabl
distinguish
previou
exposur
activ
persist
endovascular
infect
sever
studi
shown
posit
serolog
necessarili
correl
presenc
organ
atheroma
although
serolog
may
use
screen
test
lack
gold
standard
abl
confirm
presenc
activ
infect
vascular
wall
way
cholesterol
level
accur
test
evalu
hyperlipidemia
potenti
modifi
risk
factor
need
sensit
standard
mean
identifi
activ
endovascular
infect
pcr
detect
c
pneumonia
dna
peripher
blood
mononuclear
cell
may
better
marker
persist
infect
measur
effect
antichlamydi
therapi
although
organ
present
atheromat
plaqu
koch
first
postul
histopatholog
data
suggest
organ
tropism
atherosclerot
vascular
tissu
viabl
organ
cultur
tissu
koch
second
postul
howev
difficulti
cultur
organ
vitro
describ
absenc
surrog
marker
activ
infect
pose
diagnost
challeng
determin
presenc
activ
endovascular
infect
data
anim
model
provid
support
koch
third
postul
inocul
organ
healthi
host
observ
caus
atherosclerot
diseas
increas
progress
atherosclerot
lesion
preexist
diseas
anim
studi
inocul
organ
presenc
c
pneumonia
vessel
wall
confirm
koch
fourth
postul
limit
koch
postul
determin
associ
c
pneumonia
coronari
diseas
data
clinic
trial
becom
paramount
import
posit
clinic
trial
would
provid
addit
evid
favor
causal
relationship
wherea
neg
trial
would
suggest
opposit
howev
result
current
antibiot
clinic
trial
inconclus
effect
therapi
may
vari
differ
subset
patient
seen
roxi
clarifi
studi
compar
academ
wizard
trial
patient
present
acut
coronari
syndrom
may
deriv
direct
benefit
antibiot
therapi
stabl
coronari
diseas
activ
chlamydi
infect
may
involv
plaqu
ruptur
antibiot
may
import
initi
therapi
present
acut
coronari
syndrom
way
aspirin
antiplatelet
agent
bblocker
statin
use
result
proveit
ace
trial
ongo
largescal
clinic
trial
tabl
import
clarifi
potenti
role
antibiot
treatment
patient
acut
coronari
syndrom
coronari
diseas
respect
sever
import
issu
rais
clinic
trial
metabol
inact
persist
form
organ
may
make
erad
difficult
rais
question
optim
durat
antibiot
therapi
longer
durat
therapi
may
need
provid
bactericid
effect
organ
trial
demonstr
posit
treatment
benefit
need
weigh
benefit
risk
increas
antimicrobi
resist
addit
area
uncertainti
degre
antiinflammatori
effect
antibiot
account
benefit
seen
cardiovascular
outcom
sinc
manuscript
written
result
antibio
proveit
trial
releas
antibio
studi
examin
acut
mi
patient
random
roxithromycin
placebo
week
found
differ
mortal
secondari
end
point
two
group
month
proveit
studi
trial
patient
admit
acut
coronari
syndrom
show
cardiovascular
benefit
associ
longterm
year
treatment
azithromycin
lack
benefit
seen
trial
suggest
current
role
long
term
antibiot
treatment
least
current
antichlamydi
therapi
avail
manag
coronari
arteri
diseas
